Description
Global Oral Antidiabetic Drugs Market Analysis and Forecast Report 2030
Market Overview
CRI has released a report titled Oral Antidiabetic Drugs Market – Analysis of Market Size, Share & Trends for 2014 – 2020 and Forecasts to 2031. The market is anticipated to reach USD66.30billion by 2030 at CAGR of 5.6% over the period from 2021 to 2030.. According to the report, emphasizes on the detailed understanding of some decisive factors such as size, share, sales, forecast trends, supply, production, demands, industry and CAGR in order to provide a comprehensive outlook of the global market
Oral Antidiabetic Drugs Market Market: Key Players
Sanofi S.A.
Eli Lilly and Company
AstraZeneca plc
Astellas Pharma Inc.
Johnson & Johnson (Janssen Pharmaceuticals)
Boehringer Ingelheim
Merck And Co.
Takeda
Bristol Myers Squibb
Novartis
Pfizer
Segmentation
The Oral antidiabetic drugs Market is segmented asfollows:
By Drugs Class
Sulfonylureas (Glimepiride, Gliclazide, Glyburide, Others)
Meglitinides
Repaglinide
Nateglinide
Biguanides (Metformin, Others)
Alpha-glucosidase inhibitors (Acarbose, Voglibose, Others)
Others
By Type
Type 1 Diabetes
Type 2 diabetes
By End User
Hospital
Pharmacy Store
Drug Store
Diabetics Treatment Centres
Others
Oral Antidiabetic Drugs Market Market Dynamics
Oral Antidiabetic Drugs Market Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
COVID-19 pre and post business impact analysis
Detailed overview of the parent market
Changing market dynamics in the industry
In-depth market segmentation
What is the Oral Antidiabetic Drugs Market Market growth?
Which segment accounted for the largest Oral Antidiabetic Drugs Market Market share?
Who are the key players in the Griddles Market?
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint
Note: Although care has been taken to maintain the highest levels of accuracy in CRI’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Related Reports: Global Multiplex Biomarker Imaging Market (2018 – 2023)
Table of Contents
Contents
1. Executive Summary
2. Oral Antidiabetic Drugs Market
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. Average Pricing Analysis
5. Macro-Economic Indicators
6. Market Dynamics
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. Correlation & Regression Analysis
7.1. Correlation Matrix
7.2. Regression Matrix
8. Recent Development, Policies & Regulatory Landscape
9. Risk Analysis
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. Oral Antidiabetic Drugs Market Analysis
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. Oral Antidiabetic Drugs Market
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12. Oral Antidiabetic Drugs Market: Market Segmentation
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By network type: Market Share (2020-2030F)
12.2.1. Hardware , By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Software , By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.3. Services , By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By End user: Market Share (2020-2030F)
12.3.1. Manufacturing, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. Healthcare, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.3. Energy and Utilities, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.4. IT & Telecom, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.5. Automotive and Transportation, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.6. Supply Chain and Logistics, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.7. Government and Public Safety, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.8. Agriculture, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.9. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
Company Profile
Sanofi S.A.
Eli Lilly and Company
AstraZeneca plc
Astellas Pharma Inc.
Johnson & Johnson (Janssen Pharmaceuticals)
Boehringer Ingelheim
Merck And Co.
Takeda
Bristol Myers Squibb
Novartis
Pfizer
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
Reviews
There are no reviews yet.